Effect of homocysteinemia on the development of diabetic nephro- and retinopathy in adolescents

Aim.
To consider homocysteinemia in children and adolescents with diabetes mellitus (DM1) as an independent risk factor of diabetic nephro- and retinopathy (DN and DR).
Materials and methods.
Twenty nine adolescents (19 girls and 10 boys) with DM1 were examined. DN and DR were diagnosed in conformity with medical aid standards for DM1patients. Plasma homocysteine level was measured by IEA.
Results.
Plasma homocysteine level in DN patients was higher (6.4?1.6, n=10) than in DR group (5.3?1.7, n=9) and controls (5.6?1.8, n=10). Patients of all study groups werecomparable in terms of age, DM duration, and HbA_1c level.
Conclusion.
Plasma homocysteine level in DN patients was higher than in DR and control groups. It gives reason to consider this parameter as an independent risk factor alongwith some others in pathogenesis of diabetic microangiopathies (in the first place, nephropathy). Adolescents with DM1 and elevated plasma homocysteine level need additionalcorrection by specific medicines.

diabetic nephropathy, diabetic retinopathy, adolescents, homocysteinemia

1. Дедов И.И., Кураева Т.Л., Петеркова В.А. Сахарный диабет у детей и подростков. - М: ГЭОТАР-Медиа, 2007. - С. 96-99.

2. Дедов И.И., Шестакова М.В. Диабетическая нефропатия. - М.: Универсум Паблишинг, 2000. - С. 80-98.

3. Потемкин В. В., Кубатиев А. А., Абрамова Е. А. и соавт. Роль гомоцистеина в патогенезе сосудистых осложнений при сахарном диабете 2-го типа. Проблемы эндокринологии. 2007; 53 (3): 10-13.

4. Neugebauer S., Baba T., Watanabe T. Methylenetetrahydrofolate reductase gene polymorfism as a risk factor for diabetic nephropathy in NIDDM patients. Lancet. 1998; 352: 454 p.

5. Старцева А.И., Щербакова М.Ю., Пагода Т.В. Факторы развития атеросклероза. Педиатрия. 2005; (3): 93 c.

6. Refsum H., Smith A.D. Homocysteine, B vitamins and cardiovascular disease. N Engl J Med 2006; 355: 207 p.

7. Shcherbak N., Shutskaya Zh., Schwartz E. et al. Methylentetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy in IDDM patients. Moleс gen and metabol 1999; 68: 375-78.

8. Шуцкая Ж.В., Башнина Е.Б., Савенкова Н.Д. Распространенность диабетической нефропатии у больных с аллельными вариантами C667T полиморфизма гена МТГФР по результатам 7-летнего катамнеза. Нефрология. 2008; 12(1): 36-39.

9. Matteucci E., Rossi L., Marini S. Blood levels of total homocysteine in patients with type 1 diabetes (with no complications, diabetic nephropathy and/or retinopathy) and in their non-diabetic relatives. Nutr Metab Cardiovasc Dis 2002; 12(4): 184-89.

10. Шейман Д.А. Патофизиология почки. - М.: Бином, 2007. - 45 c

11. Bazzano L.A., Reynolds K., Holder K.N. et al. Effect of folic acid supplementation on risk of cardiovascular diseases. A meta-analysis of randomized controlled trials. JAMA. 2006; 296: 2720-26.